| Condition |
Intervention |
Phase |
Clinical trial identifier* |
| Infectious Diseases |
|
|
|
| Influenza virus |
Influenza DNA vaccine/Trivalent inactivated vaccine |
Phase I |
NCT01609998
NCT01498718
NCT01676402
NCT00995982 |
| |
Monovalent H5 Influenza DNA vaccine (A Vietnam/1194/2004) |
Phase I |
NCT00347529 |
| |
Trivalent DNA vaccine (PIA0601) with or without DEI-LT (pPJV2012) |
Phase I |
NCT00375206 |
| |
VCL-IPT1 and VCL-IPM1 DNA vaccines |
Phase I |
NCT00709800
NCT00694213 |
| |
Prime-boost with monovalent Influenza subunit virion (H5N1) vaccine followed by H5 DNA vaccine (VRC-AVIDNA036-00-VP) |
Phase I |
NCT01086657
NCT00776711 |
| |
H1 and H5 Influenza hemagglutinin DNA vaccines |
Phase I |
NCT01405885 |
| |
Trivalent (A/New Caledonia/20/99, A/Panama/2007/99, B/Jiangsu/10/20) DNA Influenza vaccine |
Phase I |
NCT00349037 |
| |
Recombinant H7 DNA vaccine administered alone or with monovalent Influenza subunit virion H7N9 vaccine (MIV) |
Phase I |
NCT02206464 |
| |
DNA-based Influenza vaccine (FVH1) |
Phase I |
NCT01587131 |
| |
H5 avian Influenza DNA vaccine (VGX-3400X) |
Phase I |
NCT01142362
NCT01184976 |
| |
H1 Influenza DNA vaccine (VRC-FLUDNA057-00-VP) |
Phase I |
NCT00973895 |
| |
Influenza DNA vaccine (VRC-FLUDNA047-00-VP) followed by the seasonal Influenza trivalent inactivated vaccine (TIV) |
Phase I |
NCT00858611 |
| Hemorrhagic Fever With Renal Syndrome |
Hantaan/Puumala Virus DNA Vaccine |
Phase II
Phase I |
NCT02116205
NCT01502345 |
| Venezuelan Equine Encephalitis Virus Infection |
Venezuelan Equine Encephalitis Virus DNA vaccine |
Phase I |
NCT01984983 |
| Dengue |
Dengue-1 pre-membrane/envelope DNA vaccine |
Phase I |
NCT00290147 |
| |
Tetravalent Dengue vaccine formulated with Vaxfectin® |
Phase I |
NCT01502358 |
| Chronic Hepatitis B |
HBV envelope DNA vaccine (pCMVS2.S) |
Phase I, Phase II |
NCT00536627
NCT00988767 |
| |
Mixed plasmid DNA (HB-110) vaccine |
Phase I |
NCT00513968 |
| |
pPDPSC18 DNA vaccine |
Phase I |
NCT00277576 |
| |
HB110E Hepatitis B DNA vaccine in combination with Entecavir |
- |
NCT01813487 |
| |
DNA vaccine encoding HBsAg and HBcAg (INO-1800) and a DNA plasmid encoding human IL-12 (INO-9112) |
Phase I |
NCT02431312 |
| |
VGX-6150 |
Phase I |
NCT02027116 |
| HIV |
HIV clades B and C DNA vaccine |
Phase II |
NCT01705223 |
| |
HIV gag, pro, RT, env, tat, vpu, and rev DNA vaccine (pGA2/JS2) |
Phase I |
NCT00043511
NCT00908323 |
| |
Prime-boost with pGA2/JS2 DNA vaccine followed by a modified vaccinia HIV vaccine (MVA/HIV62) |
Phase I
Phase II |
NCT00301184
NCT00820846 |
| |
Prime-boost with pGA2/JS7 DNA vaccine followed by a modified vaccinia HIV vaccine (MVA/HIV62) |
Phase I |
NCT01378156 |
| |
PENNVAX®-GP (gag, pol, env) HIV-1 DNA vaccine and a DNA plasmid encoding human IL-12 |
Phase I |
NCT02431767 |
| |
PENNVAX®-B (gag, pol, env) HIV-1 DNA vaccine and a DNA plasmid encoding human IL-12 |
Phase I |
NCT00991354 |
| |
PENNVAX®-B (gag, pol, env) HIV-1 DNA vaccine with or without a DNA plasmid encoding human IL-12 or IL-15 |
Phase I |
NCT00775424
NCT00528489 |
| |
PENNVAX™-B (gag, pol, env) administered by electroporation |
Phase I |
NCT01082692 |
| |
Prime-boost with PENNVAX-G DNA (HIV-1 env A, C, and D, and consensus gag plasmids) followed by modified vaccinia HIV vaccine (MVA-CMDR) |
Phase I |
NCT01260727 |
| |
Prime-boost with HIV-1 DNA Priming Regimens (Nat-B Env, CON-S Env, and Mosaic Env) followed by MVA-CMDR |
Phase I |
NCT02296541 |
| |
Prime-boost with HIV-1 DNA vaccine (DNA HIVIS) followed by a modified vaccinia HIV vaccine (MVA-CMDR) |
Phase I |
NCT01407497 |
| |
Prime-boost with env DNA vaccine followed by env recombinant adenovirus (AdV5 and AdV35) |
Phase I |
NCT00801697 |
| |
Prime-boost with multiclade, multigene HIV DNA vaccine followed by env recombinant adenovirus (AdV5 and AdV35) |
Phase I |
NCT00472719 |
| |
Prime-boost with multiclade HIV-1 DNA vaccine followed by a multiclade HIV-1 recombinant adenovirus (AdV5) |
Phase II |
NCT00865566 |
| |
Prime-boost with DNA-HIV-recombinant vaccine (EP-1233) followed by an HIV-recombinant viral vaccine (MVA-mBN32) |
Phase I |
NCT00428337 |
| |
HIV-1 gag DNA vaccine administered together a DNA plasmid encoding IL-15 |
Phase I |
NCT00115960 |
| |
HIV-1 DNA vaccine encoding a modified Gag-Pol protein |
Phase I |
NCT00009685 |
| |
Prime-boost with a DNA vaccine (GEO-D03) followed by a modified vaccinia HIV vaccine (MVA/HIV62) |
Phase I |
NCT01571960 |
| |
HIV-1 gag DNA vaccine administered together a DNA plasmid encoding IL-12 |
Phase I |
NCT00111605 |
| |
HIV-1 DNA vaccine encoding the env and rev genes (APL 400-003) |
Phase I |
NCT00001538
NCT00002232
NCT00002231
NCT00002350 |
| |
HIV-1 gag-pol DNA vaccine (APL-400-047) administered with bupivacaine |
Phase I |
NCT00001088 |
| |
DNA vaccines encoding HIV clades A, B and C env, clade B rev, clades A and B gag, and clade B RT |
Phase I |
NCT01140139 |
| |
Prime-boost DNA vaccine encoding multiple HIV-1 proteins (HIV-MAG) with or without a DNA plasmid encoding IL-12 followed by VSV-gag HIV vaccine |
Phase I |
NCT01578889
NCT01859325 |
| |
HIV DNA vaccine (DNA-HIV-PT123) administered with a gp120 protein vaccine (AIDSVAX®B/E) or HIV vaccine (NYVAC-HIV-PT1 and NYVAC-HIV-PT4) administered with a gp120 protein vaccine (AIDSVAX®B/E) |
Phase I |
NCT01799954 |
| |
HIV DNA vaccine (DNA-HIV-PT123) administered with a gp120 protein vaccine (AIDSVAX®B/E) |
Phase I |
NCT02376582 |
| |
Prime-boost with a HIV DNA vaccine (DNA-HIV-PT123) followed by NYVAC HIV protein vaccine (NYVAC-HIV-PT1 and NYVAC-HIV-PT4) |
Phase I |
NCT01783977 |
| |
DNA vaccine composed of 21 highly specific CTL epitopes (EP HIV-1090) |
Phase I |
NCT00054860
NCT00052182 |
| |
Prime-boost with a DNA vaccine (pSG2.HIV) followed by ChAdV63-HIV or MVA-HIV after depletion of serum amyloid P component |
Phase I, Phase II |
NCT02425241 |
| |
HIV-1 vaccine encoding the gag, env, pol, nef, and tat antigens (ADVAX) administered by electroporation |
Phase I |
NCT00545987
NCT00249106 |
| |
Prime-boost with a DNA vaccine (encoding clade B HIV-1 gag, pol and nef and HIV-1 env glycoprotein from clades A, B, and C) followed by four non-replicating AdV (encoding HIV-1 gag/pol polyproteins from clade B and HIV-1 env glycoproteins from clades A, B, and C) |
Phase I |
NCT00109629
NCT00321061 |
| |
Prime-boost with a DNA vaccine (encoding clades A, B, and C HIV gag, pol, nef, and env) followed by AdV (encoding gag, pol, and env). |
Phase I |
NCT00384787
NCT00270465 |
| |
DNA vaccine (GTU-MultiHIV B) followed by a Lipopeptide vaccine (LIPO-5) |
Phase II |
NCT01492985 |
| |
DNA vaccine encoding gag, pol, vpr, nef, rev, and env (EP HIV-1090) compared with recombinant protein vaccine containing the 18 HIV proteins from pol, vpu, and gag (EP HIV-1043) |
Phase I |
NCT00141024 |
| |
Multiclade HIV-1 DNA Vaccine (VRC-HIVDNA009-00-VP) |
Phase I,
Phase II |
NCT00071851
NCT00125099
NCT01549470
NCT00047931 |
| |
Multiclade HIV-1 DNA vaccine (VRC-HIVDNA009-00-VP) administered with IL-2/Immunoglobulin DNA vaccine |
Phase I |
NCT00069030 |
| |
Multiclade HIV-1 DNA vaccine (VRC-HIVDNA016-00-VP) |
Phase I |
NCT00089531 |
| |
Prime-boost with a multiclade HIV-1 DNA vaccine (VRC-HIVDNA016-00-VP) followed by AdV vaccine (VRC-HIVADV014-00-VP) |
Phase I |
NCT01054872
NCT01386489 |
| |
Prime-boost with a multiclade HIV-1 DNA vaccine (VRC-HIVDNA009-00-VP) followed by AdV vaccine (VRC-HIVADV014-00-VP) |
Phase I |
NCT00270218 |
| |
HIV-1 DNA vaccine expressing gag, pol, nef, and env (VRC-HIVDNA006-00-VP) |
Phase I |
NCT00045838 |
| |
B clade DNA vaccine encoding a multi-HIV antigen consisting of a synthetic fusion protein built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, RT and gp160 (GTU®). |
Phase I |
NCT02075983 |
| |
HIV-1 multi-envelope DNA vaccine (EnvDNA) |
Phase I |
NCT00187148 |
| |
Prime-boost with a multigene DNA vaccine consisting of two plasmids expressing an HIV-1 subtype C polyprotein (Gag, RT, Tat, Nef) and an HIV-1 subtype C truncated Env (SAAVI DNA-C2) followed by a recombinant MVA vaccine expressing the same immunogens (SAAVI MVA-C). |
Phase I |
NCT00574600 |
| |
DNA vaccine encoding a gag, pol and nef polypeptide and the gp140 env followed by MVA expressing gag, pol, nef and gp120 |
Phase I |
NCT01922284 |
| Plasmodium falciparum Malaria |
Polyepitope DNA Vaccine |
Phase I |
NCT01169077 |
| |
Prime-boost with a DNA vaccine followed by AdV encoding Circumsporozoite Protein and Apical Membrane Antigen 1 |
Phase I |
NCT00870987 |
| Herpes Simplex Virus Type 2 (genital herpes) |
pPJV7630 HSV-2 DNA vaccine |
Phase I |
NCT00274300
NCT00310271 |
| |
Plasmid DNA vaccine encoding one or two HSV-2 proteins (VCL-HM01 and VCL-HB01) |
Phase I, Phase II |
NCT02030301 |
| Cancer |
|
|
|
| Head and Neck Squamous Cell Cancer |
DNA plasmids encoding E6 and E7 proteins of HPV 16 and HPV 18 (VGX-3100) administered with DNA plasmid encoding human IL-12 (INO-9012) |
Phase I |
NCT02163057 |
| Aerodigestive Malignancies |
DNA plasmid encoding HPV 6 proteins (INO-3106) administered with DNA plasmid encoding human IL-12 (INO-9012) |
Phase I |
NCT02241369 |
| Cervical Cancer |
HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine |
Phase II |
NCT01304524 |
| |
pNGVL4a-CRT/E7 DNA vaccine |
- |
NCT00988559 |
| |
DNA plasmids encoding E6 and E7 proteins of HPV 16 and HPV 18 administered with DNA plasmid encoding human IL-12 |
Phase I,
Phase II |
NCT02172911 |
| |
DNA plasmids encoding E6 and E7 proteins of HPV 16 and HPV 18 (VGX-3100) |
Phase I |
NCT00685412
NCT01188850 |
| |
GX-188E |
Phase II |
NCT02139267 |
| Cervical Cancer, Precancerous Condition |
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine |
Phase I,
Phase II |
NCT00121173
NCT00788164 |
| |
pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine with or without topical Imiquimod |
Phase I |
NCT00788164 |
| Breast Cancer |
Personalized polyepitope DNA vaccine |
Phase I |
NCT02348320 |
| Metastatic Breast Cancer |
Mammaglobin-A DNA vaccine |
Phase I
Phase I |
NCT00807781
NCT02204098 |
| Breast and Ovarian Cancers |
DNA vaccine encoding the HER-2/Neu intracellular domain (pNGVL3-hICD) admixed with GM-CSF |
Phase I |
NCT00436254 |
| Ovarian Epithelial Cancer |
pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine |
Phase I |
NCT01322802 |
| Melanoma |
Xenogeneic Tyrosinase DNA Vaccine |
Phase I |
NCT00471133 |
| |
gp75 DNA vaccine |
Phase I |
NCT00034554 |
| |
gp100 DNA vaccine |
Phase I |
NCT00104845
NCT00398073 |
| |
Human tyrosinase DNA vaccine
Mouse tyrosinase DNA vaccine |
Phase I |
NCT00698100
NCT00680589 |
| |
Synchrovax®pSEM Vaccine (MKC1106-MT) |
Phase I, Phase II |
NCT00033228 |
| Lymphoma |
Xenogeneic CD20 DNA vaccine |
Phase I |
NCT00561756 |
| Lymphoplasmacytic Lymphoma |
Lymphoma immunoglobulin derived scFV-chemokine DNA vaccine |
Phase I |
NCT01209871 |
| Prostate Cancer |
DNA vaccine encoding androgen receptor ligand-binding domain (AR LBD) with or without GM-CSF |
Phase I |
NCT02411786 |
| |
DNA vaccine encoding the rhesus prostate specific antigen (rhPSA) |
Phase I, Phase II |
NCT00859729 |
| |
DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) with recombinant GM-CSF |
Phase II
Phase I |
NCT01341652
NCT00582140 |
| |
Sipuleucel-T with or without prostatic acid phosphatase DNA (pTVG-HP) Booster Vaccine |
Phase II |
NCT01706458 |
| |
pTVG-HP DNA vaccine with rhGM-CSF |
Phase II |
NCT00849121 |
| Neuroendocrine Carcinoma |
IL-12 DNA vaccine |
Phase II |
NCT01440816 |
| Pancreatic Cancer |
Vascular endothelial growth factor receptor 2 (VEGFR-2) DNA vaccine (VXM01) |
Phase I |
NCT01486329 |
| Kidney Cancer |
Human prostate-specific membrane antigen DNA vaccine |
Phase I |
NCT00096629 |
| Others |
|
|
|
| Allogeneic Hematopoietic Cell Transplant |
Cytomegalovirus therapeutic DNA vaccine (ASP0113) |
Phase II |
NCT01903928 |
| Allergic Rhinoconjunctivitisto Japanese red cedar |
DNA vaccine encoding the CryJ2- gene fused to the lysosomal associated membrane protein (CryJ2 -DNA-LAMP) |
Phase I |
NCT01707069 |
| Seasonal Allergic Rhinitis |
Amb a 1 ImmunostimulatoryOligodeoxyribonucleotide Conjugate (AIC) |
Phase II |
NCT00346086 |
